• Introduction Introduction
    • Introduction to T-DXd Introduction to T-DXd
    • Introduction to HER2 Positive BC Introduction to HER2 Positive BC
  • Study Design Study Design
  • Patient Characteristics Patient Characteristics
  • Efficacy Efficacy
    • DCO November 20, 2023 DCO November 20, 2023
    • DCO July 25, 2022 DCO July 25, 2022
  • Safety Safety
  • Additional Analyses Additional Analyses
    • Subgroup Analysis: May 21, 2021 Data Cut-off Subgroup Analysis: May 21, 2021 Data Cut-off
      • PFS and ORR Subgroup Analysis PFS and ORR Subgroup Analysis
      • Safety Data by Disease History and Prior Line of Anti-HER2 Therapy Safety Data by Disease History and Prior Line of Anti-HER2 Therapy
      • Brain Metastases Subgroup Analysis Brain Metastases Subgroup Analysis
      • Asia Subgroup Analysis Asia Subgroup Analysis
        • Background Background
        • Patient Characteristics Patient Characteristics
        • Efficacy Efficacy
        • Safety Safety
      • HEOR Subgroup Analysis HEOR Subgroup Analysis
    • Safety Update: September 7, 2021 Data Cut-off Safety Update: September 7, 2021 Data Cut-off
  • Summary Summary
dslogo
azlogo
AstraZeneca Logo

©2023 AstraZeneca. All rights reserved.

Privacy NoticeLegal NoticeCookie Policy